NCT02803970 KOrean Borderline Ovarian Tumor (KOBOT) Registry
| NCT ID | NCT02803970 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Kangbuk Samsung Hospital |
| Condition | Ovarian Neoplasms |
| Study Type | OBSERVATIONAL |
| Enrollment | 3,000 participants |
| Start Date | 1994-12 |
| Primary Completion | 2040-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 3,000 participants in total. It began in 1994-12 with a primary completion date of 2040-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The aim of this study is to collect data on Korean patients with borderline ovarian tumors.
Eligibility Criteria
Inclusion Criteria: * Patients with borderline ovarian tumors (BOTs) diagnosed, treated, and followed between November 1994 and February 2015 at institutions where placed in the Republic of Korea. * All patients undergoing gynecologic surgery for BOTs at institutions where placed in the Republic of Korea since March, 2015 Exclusion Criteria: * Patients who did not receive primary treatment or follow-up for at least 6 months at each institution were excluded from analysis
Contact & Investigator
Taejong Song, MD, PhD
PRINCIPAL INVESTIGATOR
Kangbuk Samsung Hospital
Frequently Asked Questions
Who can join the NCT02803970 clinical trial?
This trial is open to female participants only, studying Ovarian Neoplasms. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT02803970 currently recruiting?
Yes, NCT02803970 is actively recruiting participants. Contact the research team at taejong.song@gmail.com for enrollment information.
Where is the NCT02803970 trial being conducted?
This trial is being conducted at Changwon, South Korea, Seoul, South Korea, Seoul, South Korea, Seoul, South Korea.
Who is sponsoring the NCT02803970 clinical trial?
NCT02803970 is sponsored by Kangbuk Samsung Hospital. The principal investigator is Taejong Song, MD, PhD at Kangbuk Samsung Hospital. The trial plans to enroll 3,000 participants.